David J. Clark - 14 Nov 2022 Form 4 Insider Report for Trevi Therapeutics, Inc. (TRVI)

Role
Chief Medical Officer
Signature
/s/ Christopher Galletta, attorney-in-fact
Issuer symbol
TRVI
Transactions as of
14 Nov 2022
Net transactions value
$0
Form type
4
Filing time
14 Nov 2022, 15:43:53 UTC
Next filing
16 Feb 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TRVI Stock Option (right to buy) Award $0 +300,000 $0.000000 300,000 14 Nov 2022 Common Stock 300,000 $2.02 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option was granted on November 14, 2022. The 300,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on November 14, 2023 and as to the remaining 75% of the shares in equal monthly installments thereafter, through November 14, 2026.